Poseida Therapeutics, Inc. (PSTX)
Market Cap | 631.73M |
Revenue (ttm) | 151.68M |
Net Income (ttm) | -29.22M |
Shares Out | 85.95M |
EPS (ttm) | -0.68 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 268,019 |
Open | 7.32 |
Previous Close | 7.32 |
Day's Range | 7.16 - 7.47 |
52-Week Range | 1.82 - 7.64 |
Beta | 0.12 |
Analysts | Buy |
Price Target | 15.10 (+105.44%) |
Earnings Date | Mar 9, 2023 |
About PSTX
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for PSTX stock is "Buy." The 12-month stock price forecast is $15.1, which is an increase of 105.44% from the latest price.
News

Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that m...

Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that m...

Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why
Poseida Therapeutics, Inc. (PSTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition
Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a sing...

Wall Street Analysts See an 189% Upside in Poseida Therapeutics, Inc. (PSTX): Can the Stock Really Move This High?
The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to an 189.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agr...

Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or immune effector cell-associated neurotoxic...

Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 235.29% and 5,715.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo...

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
Entered into a strategic collaboration with Roche to develop allogeneic CAR-T cell therapies for hematological indications; received $110 million upfront payment and achieved the first clinical milest...

Poseida Therapeutics to Present at Two Upcoming Investor Conferences
SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition
Preclinical data to be presented highlight sustained and normalized Factor VIII activity following single dose of P-FVIII-101 for the treatment of Hemophilia A SAN DIEGO , Nov. 3, 2022 /PRNewswire/ --...

Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress
SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting
SAN DIEGO , Oct. 5, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to creat...

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022
Announced strategic collaboration with Roche, with a $110 million upfront payment, to focus on the research and development of allogeneic CAR-T cell therapies directed to hematologic malignancies Comp...

Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , Aug. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

Poseida Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

Poseida Therapeutics (PSTX) Stock Rockets 79% on Roche Deal
Source: Shutterstock Poseida Therapeutics (NASDAQ: PSTX) stock is soaring on Wednesday after the clinical-stage biotechnology company announced a deal with Roche (OTCMKTS: RHHBY). The agreement with...

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies
Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing therapies to transform cancer care, the collaboration is focused on advancing multiple exist...

Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board
SAN DIEGO , July 26, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to creat...

Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products
Publication highlights ability of Cas-CLOVER to perform multiplexed gene editing to produce allogeneic products with a high percentage of Tscm cells that may result in better tolerability and deeper c...

Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders
SAN DIEGO , June 2, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting
Preclinical data supports potential of P-ckit-ALLO1 as a less toxic preconditioning agent for hematopoietic stem cell (HSC) transplants P-ckit-ALLO1 eliminates >95% of hematopoietic stem and progenito...

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s...

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022
SAN DIEGO , May 12, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting
Preclinical data to be presented supports potential of anti-c-kit CAR-T cells as a highly specific and less toxic conditioning regimen for hematopoietic stem cell transplantation SAN DIEGO , May 2, 20...